EANS-News: Intercell and Boehringer Ingelheim Vetmedica GmbH enter into strategic partnership to develop animal vaccines

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Subtitle: -
» Worldwide agreement for the use of certain Intercell's AIP®-derived
antigens to develop and commercialize animal vaccines
» Intercell to receive upfront, option and milestone payments as well as
royalties on product net sales

Vienna (Austria), May 10, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) today
announced that it has entered into a worldwide Option and Exclusive License
Agreement under which Boehringer Ingelheim Vetmedica has the right to use
certain antigens derived from Intercell´s Antigen Identification Program (AIP®)
to develop animal vaccines. Under the agreement, Intercell will receive upfront,
option and milestone payments as well as royalties on product net sales.

"Having partnered a number of our vaccine candidates derived from our AIP® with
leading human vaccine players such as Merck and Novartis, we are very pleased to
leverage the value of this successful technology also with a major animal
vaccine company like Boehringer Ingelheim Vertmedica. This will allow us to
further potentiate the technology and explore its technological and economical
power beyond the area of human health", stated Gerd Zettlmeissl, CEO of
Intercell.

"We are pleased to partner with Intercell and to gain access to attractive
vaccine targets generated by AIP®. We are committed to develop innovative
vaccines to meet the urgent needs for the benefit of animal health," stated
Joachim Hasenmaier, CEO of Boehringer Ingelheim Vetmedica.

Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wien
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print